Results 111 to 120 of about 48,696 (305)

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

European Heart Journal, 2019
Aims After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syndrome (ACS) or ...
J. Oldgren, P. Steg, S. Hohnloser, G. Lip, Takeshi Kimura, M. Nordaby, M. Brueckmann, E. Kleine, J. T. ten Berg, Deepak L. Bhatt, C. Cannon   +10 more
semanticscholar   +1 more source

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention

Circulation. Cardiovascular Interventions, 2020
Background: The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary ...
Natalia C. Berry, L. Mauri, P. Steg, Deepak L. Bhatt, S. Hohnloser, M. Nordaby, C. Miede, Takeshi Kimura, G. Lip, J. Oldgren, J. T. ten Berg, C. Cannon   +11 more
semanticscholar   +1 more source

Intracerebral Hemorrhage: Advances, Knowledge Gaps, and Future Directions

MedComm, Volume 6, Issue 11, November 2025.
This review provides a comprehensive synthesis of current research on the epidemiology, pathophysiological mechanisms, imaging characteristics, treatment delays, clinical management strategies, neural repair, and prognostic prediction of intracerebral hemorrhage (ICH).
Tao Liu, Weiwei Jiang, Minzhi Zhang, Shangzhi Xiong, Linan Chen, Xiaoying Chen, Rongcai Jiang   +6 more
wiley   +1 more source

Pharmacometric Characterization of Dabigatran Hemodialysis [PDF]

Clinical Pharmacokinetics, 2013
Hemodialysis has been shown to be a useful method of decreasing dabigatran plasma levels in situations that require rapid elimination of this thrombin inhibitor. However, there is currently no clinical recommendation for the accelerated/optimized elimination of dabigatran via hemodialysis (e.g., flow rates, filter type, duration of dialysis).The ...
Thorsten Lehr, Thorsten Lehr, Andreas Clemens, Alexander Staab, Karl-Heinz Liesenfeld, Sebastian Härtter, Stephan Formella   +6 more
openaire   +2 more sources

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. [PDF]

, 2015
Patients at thromboembolic risk with non-valvular atrial fibrillation (AF) can now be managed either with a vitamin K antagonist (VKA) or with a fixed dose of a non-VKA oral anticoagulant (NOAC), while patients with valvular AF have been restricted to ...
De Caterina, R, John Camm, A
core   +1 more source

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation

Patient Preference and Adherence, 2014
Jiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently
Choi JC, DiBonaventura Md, Kopenhafer L, Nelson WW   +3 more
doaj  

Medication Utilization Evaluation of Dabigatran and Rivaroxaban within a Large, Multicenter Health System. [PDF]

, 2013
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health system. Methods.
Doolin, Meagan, Issacs, Alex N., Morse, Courtney, Nisly, Sarah A., Shiltz, Erin   +4 more
core   +1 more source

Association of Anaesthetists guidelines: safe vascular access 2025

Anaesthesia, Volume 80, Issue 11, Page 1381-1396, November 2025.
Summary Introduction Safe vascular access is integral to anaesthetic and critical care practice. However, despite technological and procedural advances, it remains a frequent source of adverse events and patient harm. Ensuring a safe and effective approach to the selection, insertion and care of vascular access devices should be a priority for all ...
Andrew J. Johnston, Matthew J. Simpson, Victoria McCormack, Andrew Barton, James Bennett, Anil Chalisey, Jeremy Crane, Stefanie Curry, Helen Laycock, Dhupal Patel, Teikchoon See, John Shubhaker, Kathryn Singh, Sarah Thornton   +13 more
wiley   +1 more source

Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 5, November 2025.
ABSTRACT The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity).
Saad Hanif Abbasi, Jesper Hallas, Peter Bjødstrup Jensen, Hassan Al‐Jasim, Anton Pottegård   +4 more
wiley   +1 more source

Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.

PLoS ONE, 2021
BackgroundThe RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial demonstrated that higher-risk patients with atrial fibrillation had lower rates of stroke or systemic embolism and a similar rate of major bleeding, on average, when ...
Samuel W Reinhardt, Nihar R Desai, Yuanyuan Tang, Philip G Jones, Jeremy Ader, John A Spertus   +5 more
doaj   +1 more source